« February 10, 2008 - February 16, 2008 | Main | February 24, 2008 - March 01, 2008 »

February 22, 2008

So you wanna get into publishing? (I)

"How did you get into publishing and how do I pursue a career in that field?" As the cliché goes, I wish I had a nickel for every time I've heard that question.

So, lazy as I am, I thought I would write down an answer to the second part of the question (how I specifically got into publishing is too uninteresting to write about), so that next time I get an e-mail asking me for advice on the subject I simply send a link to this post.

There are different ways to get into publishing. Let's start with copy editor. In broad terms, copy editors are in charge of correcting the style and language of the articles we accept prior to publication, as well as making sure that the changes made by the authors when they review their proofs are correctly incorporated. As language is such an important part of the job, employers tend to prefer people whose first language is English. In the case of scientific journals, scientific training is definitely a plus. However, if you have a PhD or postdoctoral experience, this position may not be for you, as you may not find it particularly stimulating from the scientific point of view. Furthermore, employers may find you overqualified for the position.

If you want to stay in closer contact with the science, there are several options.

In journals that have professional editors, such as the Nature journals, titles from the Cell Press stable and Science, research editors read submissions and decide whether something is worth sending out for external review by experts in the field. For this job, a broad understanding of and interest in science is very important. It is also necessary to be able to express your ideas (scientific and otherwise) clearly. And crucially, you must have a very thick skin, as authors don't like it when you send them a rejection letter (which happens most of the time), and they can be very aggressive in their interactions with you. For this position, we normally hire people who have 4-5 years of postdoctoral experience, but there have been cases of people who join us after relatively brief postdocs.

Another class of professional editors are reviews editors, whose job is to think about review ideas, commission articles from suitable authors, developmentally edit the papers and organize the peer-review process. Scientifically, the requirements for the position are similar than those for research editors, although our company has sometimes hired people straight from their PhD with no post-doctoral experience. The reviews editor job can be construed as more creative than the job of a research editor -- you try to develop a useful review article, as opposed to trying to find what's wrong in someone's work as a reason to turn it down. Owing to your need to develop the articles you receive, your command of English and your attention to detail need to be very good, probably more than in the case of a research editor. At Nature Medicine we don't have a reviews editor, but we have a News & Views editor, whose job is similar to what I just described.

For both jobs, it's very useful to be socially skillful, as you need to develop good relationships with the community so that they agree to write review articles, act as referees and/or submit their research to your journal. Last, all of the above jobs (particularly copy editor) require you to have the ability to work to tight deadlines -- the journals need to come out on dates that have been established at least a year in advance, and these deadlines are rather firm.

In none of these jobs appeals to you, some publishing firms recruit other types of editors, which are variously referred to as managing editor, executive editor and so on. These people may or may not make scientific decisions on papers. Instead, they often act as liaisons between authors and the editorial board of the journal -- the scientists who ultimately decide what can be sent out to peer review and choose the referees. Depending on the journal, the managing editor may also be responsible for coordinating the production process of the publication, acting as manager of the copy editors and production staff, interact with the advertising and marketing departments, and other activities that don't necessarily require you to have a PhD. For this kind of position, in fact, it varies a lot whether your scientific background is relevant or not, although I'd say that, more often than not, it is relevant.

Last, but certainly not least, there are science journalists -- people who often work for a newspaper or other periodical, either as member of staff or as freelance writer, and whose job is to report on scientific advances for the readership of the publication. Some of these journalists have a very sophisticated understanding of science, whereas others are generalists who write about science the same way they write about politics or art -- in very broad terms for a very broad audience. The key issue here is that these people tend to be journalists, not scientists. In other words, you need a degree from journalism school to get one of these jobs. That said, if you want to be a freelance writer, you can get away without a journalism degree, provided you can write in a journalistic style. Some of the people who have written in the past for Nature Medicine's News section fall in this category of scientists turned journalists, but our News editor, who is responsible for choosing the stories we'll cover every month and for editing the work of our contributors, is a journalist by training.

In part II of these post, assuming there's interest and that my colleagues in the journal don't veto the idea, I'll tell you a bit about how we go about recruiting someone when there is an opening, in case you ever need to interview for one of these jobs.

Michael's insight and beyond

In addition to the Insight on Cardiovascular Disease, edited by Nature Medicine's own Michael Basson, a couple of papers caught my attention from this past Thursday's issue of Nature.

First, the analysis of multiple sclerosis (MS) lesions by laser-capture microdissection and proteomics, which led May Han and colleagues to identify two potential therapeutic targets for the disease -- tissue factor and protein C inhibitor -- both of which participate during coagulation. Indeed, the authors went on to show that blocking the action of thrombin (which signals downstream of tissue factor) or administering activated protein C (to counter the increased levels of its inhibitor) ameliorated pathology in an animal model of MS. The image below, from the Nature paper, shows astrogliosis in a chronic MS plaque, revealed by and anti-GFAP antibody.
steinman.JPG

Second, the discovery by Xiaoyong Yang and colleagues of a link between O-GlcNac transferase and insulin resistance. We already knew that glucose flux through the hexosamine biosynthetic pathway leads O-GlcNac transferase to attach the sugar O-linked beta-N-acetylglucosamine (O-GlcNac) to proteins, thereby acting as a nutrient sensor. The new study shows that O-GlcNac transferase has a binding site for phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3), a key mediator of insulin signaling. Upon binding, PI(3,4,5)P3 recruits O-GlcNac transferase to the plasma membrane, where it sticks O-GlcNac to proteins of the insulin signaling pathway, reducing their responsiveness to insulin (see the figure below, which I borrowed from the paper; O-GlcNac transferase is labeled as OGT). In vivo, liver overexpression of O-GlcNac transferase causes insulin resistance, pointing to the likely functional relevance of this mechanism.
evans.JPG

February 20, 2008

Mutants, revertants and innate responders

Two sets of papers caught my attention over the past couple of days. Apologies if they are old hat for those of you who work in these fields. It's hard to keep up with all the ToC alerts I get.

The first is a doublet from Nature on the mechanism whereby certain tumors acquire resistence to chemotherapy. The studies, by Wataru Sakai and colleagues and by Stacey Edwards and colleagues focused on tumors that carry mutations in BRCA2 and are therefore sensitive to platinum compounds like cisplatin. In some cases, these tumors develop resistance to cisplatin, and what both studies show is that the development of resistance depends on the appearance of new mutations in BRCA2, which restore the open reading frame of the protein. Although this is perhaps not incredibly surprising, particularly because similar secondary mutations had been observed in cases of resistance to imatinib in leukemia, this finding has obvious clinical implications for people who become unresponsive to cisplatin.

The other paper, by Marielle Gold and her colleagues in PLoS Pathogens, reports on the existence of a novel population of human T cells that innately recognize Mycobacterium tuberculosis (Mtb). These cells, which the authors isolated from newborns who were very unlikely to have ever been exposed to the bacterium, exist at relatively high frequencies and respond to Mtb-infected cells by producing IFN-γ. The authors assert that this is the first demonstration of a human innate pathogen-specific T cell and refer to preliminary experiments showing that other thymocytes can also respond to other pathogens including Staphylococcus aureus and Escherichia coli. How this innate recognition comes about in the fisst place strikes me as a pretty interesting question for follow-up studies.

Science Debate

The AAAS meeting last weekend was abuzz with events related to the US elections, including a forum where representatives of the Clinton and Obama campaigns presented their viewpoints of science policy.

I've been having trouble figuring out the difference between the two candidates' positions on any issue, so was eager to learn something from from the source.

Perhaps reflecting the stereotypes of the two campaigns, the Clinton representative, Tom Kalil, presented a more detailed, wonky set of proposals. Kalil was Deputy Assistant to former President Bill Clinton for Technology and Economic Policy. He said Clinton would double the budgets of specific agencies, including the National Institutes of Health, the National Science Foundation and the National Institute of Standards and Technology. She also would establish a $50 billion "Strategic Energy Fund" in part to promote renewable energy.

Obama's representiative, Alec Ross, looked about 20 years old and is the exective vice-president of One Economy, a nonprofit corporation that seeks to expand broadband technolgy. Perhaps in keeping with that, he emphasized computer technology advances, such as an expansion of high speed internet access. But he also said Obama planned to double funding of basic research and establish a $150 billion ten-year energy program.

Both candidates proposed programs to create electronic medical records--something that could also aid researchers conducting clinical trials.

I must admit I left still wondering essentially what the difference is between the two candidates. And I also wish someone from the McCain campaign could have been there (his campaign said they had scheduling conflicts). So I'm all for an effort to get the candidates together for a "Science Debate" an idea that is gaining a lot of momentum (although maybe not among the candidates themselves).

What do you think? Is science important enough for it's own debate? Are you ready to get behind the effort?

http://www.sciencedebate2008.com/www/index.php

Consider the Abalone

It has been too long since I have blogged, and going to a meeting seems like a good reason to start up again. I spent the weekend in Boston at the annual meeting of the American Association for the Advancement of Science. 



The most interesting talk, by Angela Belcher at MIT, had on the surface very little to do with medicine. But it was so cool I have to blog about it.  Well, Belcher says she is applying her techniques to medical devices. And she does work on viruses—bacteriophage, to be more exact. 



Phage are viruses that infect bacteria, and it’s easy to make zillions in a test tube.  Belcher is using phage engineered to produce various proteins on their coats that nucleate the formation of inorganic materials—such as the building blocks of a solar cell, or lattices of cobalt oxide to create a battery electrode. 



She uses a technique often used by biologists, called ‘phage display’ in which phages within a large population each display unique peptides on their coats.  She can then screen for the phages that have the properties she is interested in, such as the ability to seed the formation of inorganic lattices of a particular confirmation. She further hones the properties of her phage—and the materials they seed—by natural selection.

She says she is inspired by the designs of nature—such as that of the abalone. Abalone shells are primarily calcium carbonate, a substance that by itself is soft and chalky. It's proteins within the shell that prompt the calcium carbonate to assume a particularly tough and resilient conformation. 



Her goal is to generate materials that are ecologically friendly, replicable, and assemble at room temperature. She also wants her materials to be upscalable—something her lab could achieve, for instance, with successive dips of an electrode in a beaker of phage, and a beaker of inorganic material that assembles into place using the phage as a template. 

Archives

Powered by
Movable Type 3.2